Pirfenidone News and Research

RSS
Pulmospheres could serve as personalized, predictive model for assessing effect of IPF drugs

Pulmospheres could serve as personalized, predictive model for assessing effect of IPF drugs

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

First Edition: May 19, 2014

First Edition: May 19, 2014

PFF Patient Communication Center: The destination for latest disease education information

PFF Patient Communication Center: The destination for latest disease education information

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune reaches definitive agreement with Vidara to sell Actimmune

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

IQWiG publishes report on Esbriet benefit assessment for treatment of IPF

IQWiG publishes report on Esbriet benefit assessment for treatment of IPF

InterMune reports new data from Esbriet clinical trial on IPF

InterMune reports new data from Esbriet clinical trial on IPF

InterMune to launch Esbriet for German patients with IPF

InterMune to launch Esbriet for German patients with IPF

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis